CN103435631A - I型硫酸氢氯吡格雷的制备方法 - Google Patents
I型硫酸氢氯吡格雷的制备方法 Download PDFInfo
- Publication number
- CN103435631A CN103435631A CN2013103860255A CN201310386025A CN103435631A CN 103435631 A CN103435631 A CN 103435631A CN 2013103860255 A CN2013103860255 A CN 2013103860255A CN 201310386025 A CN201310386025 A CN 201310386025A CN 103435631 A CN103435631 A CN 103435631A
- Authority
- CN
- China
- Prior art keywords
- clopidogrel
- free alkali
- thiophene
- chloro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 title abstract description 6
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 title abstract description 6
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 99
- 239000003513 alkali Substances 0.000 claims abstract description 62
- 239000012535 impurity Substances 0.000 claims abstract description 34
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000007670 refining Methods 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 71
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 51
- 229960003009 clopidogrel Drugs 0.000 claims description 49
- 229950005953 camsilate Drugs 0.000 claims description 43
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 239000012074 organic phase Substances 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- 239000007795 chemical reaction product Substances 0.000 claims description 12
- 230000003292 diminished effect Effects 0.000 claims description 12
- 239000012065 filter cake Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 11
- 235000011152 sodium sulphate Nutrition 0.000 claims description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 9
- 235000019253 formic acid Nutrition 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 238000013517 stratification Methods 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 6
- 229920002866 paraformaldehyde Polymers 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 230000006340 racemization Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- SOJSYOXMFGDLHY-UHFFFAOYSA-N methyl acetate;hydrochloride Chemical compound Cl.COC(C)=O SOJSYOXMFGDLHY-UHFFFAOYSA-N 0.000 abstract 1
- 239000003208 petroleum Substances 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 0 *[C@](c(cccc1)c1Cl)NCCc1ccc[s]1 Chemical compound *[C@](c(cccc1)c1Cl)NCCc1ccc[s]1 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N CC(C)(C(CC1)C2)C1(CS(O)(=O)=O)C2=O Chemical compound CC(C)(C(CC1)C2)C1(CS(O)(=O)=O)C2=O MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940020573 plavix Drugs 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XHEPLGDLOCEVPX-UHFFFAOYSA-N CC(C1C2)C1(C1)C1(CS(O)(=O)=O)C2=O Chemical compound CC(C1C2)C1(C1)C1(CS(O)(=O)=O)C2=O XHEPLGDLOCEVPX-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-UHFFFAOYSA-N COC(C(c(cccc1)c1Cl)N(CC1)Cc2c1[s]cc2)=O Chemical compound COC(C(c(cccc1)c1Cl)N(CC1)Cc2c1[s]cc2)=O GKTWGGQPFAXNFI-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310386025.5A CN103435631B (zh) | 2013-08-29 | 2013-08-29 | I型硫酸氢氯吡格雷的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310386025.5A CN103435631B (zh) | 2013-08-29 | 2013-08-29 | I型硫酸氢氯吡格雷的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103435631A true CN103435631A (zh) | 2013-12-11 |
CN103435631B CN103435631B (zh) | 2015-08-26 |
Family
ID=49689369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310386025.5A Active CN103435631B (zh) | 2013-08-29 | 2013-08-29 | I型硫酸氢氯吡格雷的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103435631B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014118802A1 (en) * | 2013-01-31 | 2014-08-07 | Pharmazell Gmbh | An improved process for the preparation of clopidogrel bisulfate form-i |
CN104945413A (zh) * | 2015-07-21 | 2015-09-30 | 浙江华海药业股份有限公司 | 一种硫酸氢氯吡格雷晶型i制备方法 |
CN108051528A (zh) * | 2018-02-05 | 2018-05-18 | 成都倍特药业有限公司 | 从药物中检测樟脑磺酸酯类化合物的方法 |
CN110590805A (zh) * | 2019-09-11 | 2019-12-20 | 天方药业有限公司 | 高纯度ii晶型硫酸氢氯吡格雷的制备方法 |
CN110804063A (zh) * | 2019-11-14 | 2020-02-18 | 天方药业有限公司 | 高纯度氯吡格雷的合成方法 |
CN112110879A (zh) * | 2020-10-21 | 2020-12-22 | 扬州中宝药业股份有限公司 | 一种舒欣啶游离碱的制备方法 |
CN113880858A (zh) * | 2021-11-08 | 2022-01-04 | 成都化润药业有限公司 | 一种硫酸氢氯吡格雷杂质a及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204469A (en) * | 1990-07-10 | 1993-04-20 | Sanofi | Process for the preparation of an n-phenylacetic derivative of tetrahydrothieno(3,2-c)pyridine and its chemical intermediate |
CN1690060A (zh) * | 2004-04-19 | 2005-11-02 | 上海开特国际贸易有限公司 | 一种制备i型硫酸氯吡格雷的方法 |
CN101333223A (zh) * | 2008-07-28 | 2008-12-31 | 台州市知青化工有限公司 | 氯吡格雷及其盐的制备方法 |
CN101348490A (zh) * | 2008-08-18 | 2009-01-21 | 深圳海王药业有限公司 | 氯吡格雷及其盐的制备方法 |
CN103044444A (zh) * | 2013-01-21 | 2013-04-17 | 上海现代哈森(商丘)药业有限公司 | 一种高纯度ⅰ型(+)-(s)-硫酸氢氯吡格雷的合成方法 |
-
2013
- 2013-08-29 CN CN201310386025.5A patent/CN103435631B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204469A (en) * | 1990-07-10 | 1993-04-20 | Sanofi | Process for the preparation of an n-phenylacetic derivative of tetrahydrothieno(3,2-c)pyridine and its chemical intermediate |
CN1690060A (zh) * | 2004-04-19 | 2005-11-02 | 上海开特国际贸易有限公司 | 一种制备i型硫酸氯吡格雷的方法 |
CN101333223A (zh) * | 2008-07-28 | 2008-12-31 | 台州市知青化工有限公司 | 氯吡格雷及其盐的制备方法 |
CN101348490A (zh) * | 2008-08-18 | 2009-01-21 | 深圳海王药业有限公司 | 氯吡格雷及其盐的制备方法 |
CN103044444A (zh) * | 2013-01-21 | 2013-04-17 | 上海现代哈森(商丘)药业有限公司 | 一种高纯度ⅰ型(+)-(s)-硫酸氢氯吡格雷的合成方法 |
Non-Patent Citations (1)
Title |
---|
储刚等: "I晶型硫酸氢氯吡格雷的合成", 《中国新药杂志》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014118802A1 (en) * | 2013-01-31 | 2014-08-07 | Pharmazell Gmbh | An improved process for the preparation of clopidogrel bisulfate form-i |
CN104945413A (zh) * | 2015-07-21 | 2015-09-30 | 浙江华海药业股份有限公司 | 一种硫酸氢氯吡格雷晶型i制备方法 |
CN108051528A (zh) * | 2018-02-05 | 2018-05-18 | 成都倍特药业有限公司 | 从药物中检测樟脑磺酸酯类化合物的方法 |
CN110590805A (zh) * | 2019-09-11 | 2019-12-20 | 天方药业有限公司 | 高纯度ii晶型硫酸氢氯吡格雷的制备方法 |
CN110804063A (zh) * | 2019-11-14 | 2020-02-18 | 天方药业有限公司 | 高纯度氯吡格雷的合成方法 |
CN110804063B (zh) * | 2019-11-14 | 2021-01-05 | 天方药业有限公司 | 氯吡格雷的合成方法 |
CN112110879A (zh) * | 2020-10-21 | 2020-12-22 | 扬州中宝药业股份有限公司 | 一种舒欣啶游离碱的制备方法 |
CN112110879B (zh) * | 2020-10-21 | 2022-07-26 | 扬州中宝药业股份有限公司 | 一种舒欣啶游离碱的制备方法 |
CN113880858A (zh) * | 2021-11-08 | 2022-01-04 | 成都化润药业有限公司 | 一种硫酸氢氯吡格雷杂质a及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103435631B (zh) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103435631B (zh) | I型硫酸氢氯吡格雷的制备方法 | |
CN102249998B (zh) | 一种制备顺苯磺酸阿曲库铵的方法 | |
CN102020636A (zh) | 盐酸法舒地尔的合成及提纯方法 | |
CN101962379B (zh) | 一种磺酰基异喹啉衍生物的精制方法 | |
CN103242260A (zh) | 一种制备苯并吩硒嗪光敏剂的方法 | |
CN102850347B (zh) | 一种吡唑衍生物或其盐的拆分方法 | |
CN114213327A (zh) | 一种(-)-石杉碱甲的合成方法 | |
CN102887841A (zh) | 化合物丹磺酰氯的制备方法 | |
CN102485723A (zh) | 一锅法半合成长春西汀及其水溶性盐制备 | |
CN102702191A (zh) | 长春西汀的合成方法 | |
CN102993032A (zh) | 一种盐酸甲氧明的合成方法 | |
CN111018819B (zh) | 一种木犀草素的制备方法 | |
CN102190647A (zh) | 一种奈比洛尔的中间体的制备方法 | |
CN103922925B (zh) | 一种非诺贝酸的生产工艺 | |
CN101492455A (zh) | 光学纯左旋三尖杉碱和分离提纯方法 | |
CN101434540B (zh) | α-氯(2-氯)苯乙酸甲酯的合成方法 | |
CN103524525A (zh) | 从青蒿素生产废弃物中提取青蒿酸及其衍生物的方法 | |
CN113135876A (zh) | 艾日布林及其中间体的制备方法 | |
CN103214485B (zh) | 一种适合工业化生产高纯度9-羟基利培酮的方法 | |
CN102617461A (zh) | 一种精制阿立哌唑的新方法 | |
CN104761599A (zh) | 一种5,4’-二羟基黄酮-7-o-d-葡萄糖醛酸的制备方法 | |
CN104557965B (zh) | β‑蒿甲醚的制备工艺 | |
CN106496089B (zh) | 一种制备奥拉西坦的方法 | |
CN107759618B (zh) | 布林佐胺及其中间体的制备方法 | |
CN101921283B (zh) | 一种藤黄酸的提取工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 614000 Leshan hi tech Industrial Development Zone, Yingbin Avenue, No. 6, Sichuan Applicant after: SICHUAN EMEISHAN PHARMACEUTICAL Co.,Ltd. Address before: 614000 Leshan hi tech Industrial Development Zone, Yingbin Avenue, No. 6, Sichuan Applicant before: CHENGDU RONGYAO GROUP SICHUAN CHANGWEI PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHENGDU RONGYAO GROUP SICHUAN CHANGWEI PHARMACEUTICAL CO., LTD. TO: SICHUAN EMEISHAN PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 614000 Leshan hi tech Industrial Development Zone, Yingbin Avenue, No. 6, Sichuan Patentee after: Emei Mountain in Sichuan Pharmaceutical Co.,Ltd. Address before: 614000 Leshan hi tech Industrial Development Zone, Yingbin Avenue, No. 6, Sichuan Patentee before: SICHUAN EMEISHAN PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of type I clopidogrel hydrogen sulfate Effective date of registration: 20200421 Granted publication date: 20150826 Pledgee: Science and Technology Branch of Leshan Commercial Bank Co.,Ltd. Pledgor: Emei Mountain in Sichuan Pharmaceutical Co.,Ltd. Registration number: Y2020980001669 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210414 Granted publication date: 20150826 Pledgee: Science and Technology Branch of Leshan Commercial Bank Co.,Ltd. Pledgor: Emei Mountain in Sichuan Pharmaceutical Co.,Ltd. Registration number: Y2020980001669 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of clopidogrel bisulfate I Effective date of registration: 20210521 Granted publication date: 20150826 Pledgee: Science and Technology Branch of Leshan Commercial Bank Co.,Ltd. Pledgor: Emei Mountain in Sichuan Pharmaceutical Co.,Ltd. Registration number: Y2021510000072 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20150826 Pledgee: Science and Technology Branch of Leshan Commercial Bank Co.,Ltd. Pledgor: Emei Mountain in Sichuan Pharmaceutical Co.,Ltd. Registration number: Y2021510000072 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation Method of Type I Hydrogen Sulfate Clopidogrel Granted publication date: 20150826 Pledgee: Science and Technology Branch of Leshan Commercial Bank Co.,Ltd. Pledgor: Emei Mountain in Sichuan Pharmaceutical Co.,Ltd. Registration number: Y2024510000078 |